Phase 2 N=63 Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
HIV Infection · Bone Loss · Osteopenia
Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
Phase 4 N=66 A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
Post Menopausal Osteoporosis
Primary: Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen Concentration (sCTX) From Baseline to Day 3 — -70.16; -5.96 Percent change — p=< 0.0001
Phase 4 N=27 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
Postmenopausal Osteoporosis
Primary: Bone Turnover Marker (Blood Sample) — -7; 43 percentage of change in CTX
Phase 2 N=74 Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
Healthy
Primary: Change in C-terminal Telopeptide of Type I Collagen [CTX] — -4.1; 13.7; -7.7 percent change — p=0.611
N/A N=9 Exercise Mode and Acute Bone Resorption
Osteoporosis · Aging
Primary: C-telopeptide of Type I Collagen (CTX) Change — 0.09; 0.08 ng/mL
Phase 3 N=23 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Osteoporosis, Postmenopausal · Osteoporosis · Osteoporosis Vertebral
Primary: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3 — 5.74; 18.66 percentage of MS/BS — p=<0.0001
N/A N=147 Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid Arthritis · Bone Resorption · Ankylosing Spondylitis
Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2
Phase 4 N=43 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
Osteoporosis, Postmenopausal · Periodontitis
Primary: Sost Values for 6th Month — 1389.177; 1085.405; 1596.585; 2131.87 ng/ml — p=<0.01
Phase 4 N=34 Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
Postmenopausal Osteoporosis
Primary: Cancellous Bone Formation Rate at Month 3 — 0.13; 0.01; 0.06 mm3/mm2/day
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 2 N=15 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Number of Participants With Normal/Abnormal Bone Histology — 15; 15; 15; 0 Participants
Phase 4 N=61 Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Osteoporosis
Primary: Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion. — -2.1; -4.3; -3.0 percentage change
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
N/A N=19 Role of T-cells in Post-Menopausal Osteoporosis
Osteoporosis
Primary: Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells — 3.6; 1.8 percentage of CD3 positive cells
Phase 2 N=26 Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation
Tooth Loss
Primary: Bone Mineral Density of Bone Core — .79; .78 mg/mm^3
Phase 3 N=61 Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
Postmenopausal Women With Osteoporosis
Primary: Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Core Study Baseline, Month 6, Intention to Treat (ITT) Population — 6.2217; 12.7784 Percent Change
N/A N=9 Bioactive Glass (Sol-gel) for Alveolar Bone Regeneration After Surgical Extraction
Bone Loss · Vertical Alveolar Bone Loss · Horizontal Alveolar Bone Loss
Primary: Change in Alveolar Crestal Bone Height — 0.32; 0.84; 1.59; 0.96 mm
Phase 4 N=83 The Effects of Potassium Citrate on Bone Metabolism
Bone Diseases, Metabolic · Osteoporosis, Postmenopausal
Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Phase 2 N=57 The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Change in Bone Mineral Density · Change in Bone Marrow Fat Content
Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…
Phase 4 N=69 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…
N/A N=10 Effect of Thiazolidinediones on Human Bone
Osteoblast · Adipocytes · Bone Density
Primary: Percent Change in Number of Osteoblast and Adipocyte Colony Forming Units Cultured From Bone Marrow Stem Cells Harvested 6 Months After Treatment With Study Drug…
N/A N=86 Bone Regenerative Techniques in Endodontic Microsurgery
Apical Periodontitis
Primary: 2D Radiographic Healing at 12 Months Follow up (Overall Cases) — 24; 29; 1; 1 osteotomy site
Phase 4 N=109 Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline in Urine N-telopeptide of Type 1 Collagen (NTx.) — 49.054; 44.460; 23.676; 34.183 nM BCE/mM Cr
Phase 3 N=78 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
Phase 4 N=26 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
Osteoporosis
Primary: Serum Markers of Skeletal Turnover (Serum CTX) — 0.9887; 0.5445 ng/mL
Phase 2 N=42 Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Renal Transplant Osteodystrophy
Primary: Bone Mineral Density of Spine at 6 Months — 0.98; 0.97 gm/cm^2
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 4 N=20 Effect of Atorvastatin on Bone-vascular Axis
Osteoporosis · Hypercholesterolemia
Primary: Relative Change in OPG/RANK/RANKL mRNA Expression in Isolated T Cells and Monocytes — 0.76 relative fold change — p=<0.05